Introduction {#s1}
============

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with abdominal pain, bloating and altered bowel habits ([@B1]). It affects 11% of the world-wide population ([@B2]). IBS reduces health-related quality of life (HRQOL) ([@B4]; [@B3]) and leads to a significant economic healthcare burden. Although the exact etiology and pathogenesis underlying IBS are still incompletely understood, studies show that IBS was associated with the gastrointestinal (GI) microbiota, chronic low-grade mucosal inflammation, altered regulation of the gut-brain axis, immune function, visceral hypersensitivity, and psychosocial factors([@B6]; [@B5]; [@B7]). Since there is no effective cure for IBS, the treatment focuses on alleviating the particular symptoms. New therapeutic options for IBS include tricyclic antidepressants ([@B8]), spasmolytics ([@B9]), selective serotonin reuptake inhibitors ([@B10]), lubiprostone ([@B11]) and linaclotide ([@B12]), and 5-hydroxytryptamine type-3 antagonists such as ramosetron and alosetron ([@B13]). However, current treatments are not very useful or may cause adverse reactions ([@B14]).

Evidence ([@B15]; [@B16]) has suggested that intestinal microorganisms play an important role in IBS, as numerous studies have indicated that an irregular composition or metabolic activity of intestinal flora in patients with IBS ([@B21]; [@B18]; [@B19]; [@B20]; [@B17]). Therefore, the regulation of the gut microbiota by probiotics is a promising treatment for IBS ([@B22]). Probiotics can improve intestinal ﬂora and limit colonization of pathogenic bacteria ([@B23]). Investigators have performed numerous clinical trials to assess the efficacy of probiotics for IBS. However, the conclusions have been controversial. Some trials have suggested that probiotics can improve global IBS symptoms ([@B24]). Others have demonstrated no effect ([@B25]). Several articles have not found an apparent effect of probiotics on global IBS symptoms, but have found improvement of individual IBS symptoms ([@B26]). Therefore, we conducted this meta-analysis to examine the efficacy of global IBS symptoms improvement, global symptoms scores, and individual symptom scores, such as abdominal pain and bloating. Additionally, this study evaluated the safety of probiotics.

Methods {#s2}
=======

Search Strategy and Selection Criteria {#s2_1}
--------------------------------------

We included all eligible randomized placebo-controlled, trials (RCTs) of probiotics treatment in adult IBS. We searched Medline(1966 to Jan 2019), Embase(1974 to Jan 2019), the Cochrane Central Register of Controlled Trials(up to Jan 2019), the ClinicalTrials.gov trials register(up to Jan 2019), and Chinese Biomedical Literature Database(CBM) (1978 to Jan 2019) for relevant trials. We used the terms "probiotics" and "irritable bowel syndrome" both as medical subject heading (Mesh) and free text terms. The exact search strategy in Medline was ("probiotics"\[MeSH Terms\] OR "probiotics"\[Title/Abstract\]) AND ("irritable bowel syndrome"\[MeSH Terms\] OR "irritable bowel syndrome"\[Title/Abstract\]) AND ("randomized controlled trial" \[pt\] OR "randomized controlled trial" \[tiab\]).

We used the following eligibility criteria: (1) the studies were randomized controlled trials (RCTs) comparing probiotics with placebo; (2) diagnostic criteria included but were not limited to the Manning criteria, and Rome I, Rome II, or Rome III criteria. We did not exclude trials in which patients were stated to be diagnosed with IBS but no diagnostic criteria were described; (3) the age of participants were ≥ 18 years; (4) minimum treatment duration was 7 days. Studies were excluded if they met: (1) studies with inadequate information; (2) probiotics along with other drugs; (3) control group was not placebo; (4) data were not available after contacting the authors. There were no language limitation. Articles in foreign language were translated as needed.

Outcome Assessment {#s2_2}
------------------

The primary outcomes were the efficacy of probiotics on global IBS symptoms improvement or response to therapy. Secondary outcomes involved the effect on global symptoms scores and individual symptom scores, such as abdominal pain and bloating. The safety of probiotics was also evaluated.

Data Extraction {#s2_3}
---------------

Two reviewers extracted data from included trials independently. All data was inspected by a third reviewer. Any divergence was solved by consensus. Following data were extracted:author publication year, country, type of IBS(%), diagnostic criteria for IBS, recruitment, sample size, number of male/female, age, probiotic, dosage, duration of therapy, criteria to define symptom improvement or response, and outcomes.

Assessment of Risk of Bias {#s2_4}
--------------------------

Two reviewers performed the assessment of study quality independently. Disagreements were solved by discussion. The risk of bias were evaluated according to the Cochrane handbook ([@B27]). Random sequence generation and allocation concealment(selection bias), blinding of participants and personnel(performance bias), blinding of outcome assessment(detection bias), incomplete outcome data(attrition bias), selective reporting(reporting bias), and other biases were assessed.

Statistical Analyses {#s2_5}
--------------------

Random effects model was used ([@B28]) to get a conservative estimation for the effect. As dichotomous outcomes, the efficacy on global IBS symptoms improvement or overall symptom response and the safety of probiotics were evaluated by RR(risk ratio) and 95% CIs(confidence intervals). As continuous outcomes, global symptoms scores, and individual symptoms scores were assessed using standardised mean difference (SMD) and corresponding 95% CIs. A negative SMD was defined to indicate beneficial effects of probiotics compared with placebo for outcomes. Subgroup analyses based on probiotic type, dosage, and treatment duration were conducted.

Heterogeneity was tested by I^2^ statistic and the Cochran Q-test. I^2^ ≥ 50 and P \< 0.10 were considered as a significant heterogeneity ([@B29]). When there was significant heterogeneity, sensitivity analyses were conducted to give possible explanation. Review Manager version 5.3.5 (the Nordic Cochrane Center, Copenhagen, Denmark) was used to obtain forest plots of RRs and SMDs Egger test ([@B30]) (P \< 0.10 defined existence of possible publication bias) and funnel plots was calculated by Stata Statistical Software: Release 13 (StataCorp LP; College Station, TX).

Result {#s3}
======

Based on network searching, a total of 4,830 citations were retrieved. By removing duplicates and screening titles and abstracts, 220 studies remained to be relevant ([**Figure 1**](#f1){ref-type="fig"}). Excluding 161 studies for diverse reasons, 59 studies ([@B31]; [@B32]; [@B33]; [@B34]; [@B35]; [@B36]; [@B37]; [@B38]; [@B39]; [@B40]; [@B41]; [@B42]; [@B43]; [@B44]; [@B45]; [@B46]; [@B47]; [@B48]; [@B49]; [@B50]; [@B51]; [@B52]; [@B53]; [@B54]; [@B55]; [@B56]; [@B57]; [@B58]; [@B59]; [@B60]; [@B61]; [@B62]; [@B63]; [@B64]; [@B25]; [@B65]; [@B66]; [@B67]; [@B68]; [@B69]; [@B70]; [@B71]; [@B26]; [@B72]; [@B73]; [@B74]; [@B75]; [@B76]; [@B24]; [@B77]; [@B78]; [@B18]; [@B19]; [@B20]; [@B79]; [@B80]; [@B81]; [@B82]; [@B83]), which contained 6,721 participants, were eligible evaluating. The agreement between the two researchers was well established (kappa value = 0.91). The characteristics of the included RCTs are presented in [**Table 1**](#T1){ref-type="table"}. The risk of bias was shown in [**Figure 2**](#f2){ref-type="fig"} and [**Figure 3**](#f3){ref-type="fig"}. Twenty-three studies did not describe the details of the sequence generation process ([@B32]; [@B33]; [@B37]; [@B40]; [@B41]; [@B42]; [@B44]; [@B47]; [@B48]; [@B49]; [@B51]; [@B58]; [@B59]; [@B25]; [@B67]; [@B69]; [@B70]; [@B26]; [@B74]; [@B19]; [@B81]; [@B82]; [@B83]), and 35 studies did not describe the method of allocation concealment ([@B31]; [@B32]; [@B33]; [@B35]; [@B37]; [@B38]; [@B39]; [@B40]; [@B41]; [@B42]; [@B44]; [@B47]; [@B48]; [@B49]; [@B51]; [@B53]; [@B57]; [@B58]; [@B59]; [@B63]; [@B25]; [@B67]; [@B69]; [@B70]; [@B71]; [@B72]; [@B73]; [@B76]; [@B77]; [@B19]; [@B20]; [@B79]; [@B80]; [@B82]; [@B83]), which lead to an unclear risk of selection bias. The risk of blinding the participants and personnel was low, except two studies ([@B47]; [@B70]) were at high risk and one ([@B58]) was unclear. The risk of outcome assessment was mostly unclear. However, one study ([@B70]) was an unblinded controlled trial, leading to a high risk of performance and detection bias. Attrition bias, reporting bias, and other biases were low.

![Flow diagram of the study selection process.](fphar-11-00332-g001){#f1}

###### 

Characteristics of randomized controlled trials of probiotics versus placebo in irritable bowel syndrome.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study    Year   Country              Type of IBS(%)        diagnostic criteria for IBS   recruitment                                     Sample size   Sex (Male/Female)   Age\[years\],mean ± SD   Probiotic                                    Probiotic dosage(CFU/D)                                                                                      Duration of therapy                                                                                                                      Criteria used to define symptom improvement following therapy or response   Outcome                                                                                                                                                                        
  -------- ------ -------------------- --------------------- ----------------------------- ----------------------------------------------- ------------- ------------------- ------------------------ -------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------
  [@B31]   1989   *Denmark*            all types             Manning                       Primary care                                    54            5/27                7/15                     34                                           Streptococcus faecium                                                                                        Not stated                                                                                                                               4 weeks                                                                     IBS symptoms "improved"                                                                                                                                                        Improvement in IBS symptoms\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B32]   2000   *Sweden*             all types             Rome I                        Advertisement                                   52            9/16                7/20                     51                                           Lactobacillus plantarum                                                                                      5×10^7^                                                                                                                                  4 weeks                                                                     \> 1.5 improvement in VAS scale for\                                                                                                                                           Abdominal pain(VAS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     abdominal pain, and continuous\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     scale for IBS symptoms                                                                                                                                                         

  [@B33]   2001   Poland               all types             clinical diagnosis            Primary care                                    40            5/15                3/17                     45                                           Lactobacillus plantarum                                                                                      2×10^10^                                                                                                                                 4 weeks                                                                     improvement in IBS symptoms                                                                                                                                                    Improvement in IBS symptoms\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B34]   2003   USA                  D:100                 Rome II                       Secondary care                                  25            2/10                5/8                      42.8 ± 16.7                                  Combination                                                                                                  9×10^11^                                                                                                                                 8 weeks                                                                     Satisfactory relief of IBS symptoms for 50% of weeks, and continuous scale for IBS symptoms                                                                                    Response(Satisfactory relief of IBS symptoms for 50% of weeks)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Overall symptoms score\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B45]   2005   Finland              D:48\                 Rome I and II                 Advertising                                     103           13/39               11/40                    46                                           Combination                                                                                                  8--9×10^9^                                                                                                                               6 months                                                                    Relief of IBS symptoms, and continuous scale for IBS symptoms                                                                                                                  Global symptoms score\
                                       C:23\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Abdominal pain(a 4-point numerical scale)\
                                       A:29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adverse events

  [@B36]   2005   USA                  D:42\                 Rome II                       Secondary care and advertising                  48            3/21                0/24                     43                                           Combination                                                                                                  9×10^11^                                                                                                                                 4-8 weeks                                                                   Satisfactory relief of IBS symptom for 50% of weeks                                                                                                                            Response(Satisfactory relief of IBS symptoms for 50% of weeks)\
                                       C:33\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Bloating(100-mmVAS)\
                                       A:25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Abdominal pain(100-mmVAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B37]   2005   Israel               D:37\                 Rome II                       Secondary care                                  54            7/20                11/16                    45.6                                         L. reuteri ATCC 55730                                                                                        4×10^8^ for 1wk, then 2×10^8^                                                                                                            6 months                                                                    continuous scale for IBS symptoms                                                                                                                                              Global symptoms score\
                                       C:18.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Adverse events
                                       M:44.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  [@B38]   2005   Ireland              D:28\                 Rome II                       Secondary care                                  75            not stated          44.3                     L. salivarius UCC4331 or B. infantis 35624   1×10^10^                                                                                                     8 weeks                                                                                                                                  Continuous scale for IBS symptoms                                           Global symptoms score\                                                                                                                                                         
                                       C:26\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Abdominal pain(7-point Likert score)\                                                                                                                                          
                                       A:45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Bloating(7-pointLikert score)\                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Adverse events                                                                                                                                                                 

  [@B39]   2006   Korea                D:70\                 clinical diagnosis            Secondary care                                  34            14/3                11/6                     39.35 ± 11.9                                 Combination                                                                                                  3×10^9^(Bacillus subtilis)\                                                                                                              4 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Bloating(10-pointVAS)\
                                       A:30                                                                                                                                                                                                                                                                                                                     2.7×10^10^(Streptococcus faecium)                                                                                                                                                                                                                                                                                                                                                                   Abdominal pain(10-pointVAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B40]   2006   Sweden               all types             Rome II                       Advertising                                     76            not stated          40                       L.plantarum DSM 9843                         2×10^10^                                                                                                     6 weeks                                                                                                                                  Continuous scale for IBS symptoms                                           Global symptoms score(IBS-SSS)                                                                                                                                                 

  [@B41]   2006   UK                   D:55.5\               Rome II                       Primary care                                    362           0/270               0/92                     41.9 ± 10.46                                 B. infantis 35624                                                                                            1×10^6^,1×10^8^,1×10^10^                                                                                                                 4 weeks                                                                     Subjects\' Global Assessment (SGA) of IBS symptoms,and continuous scale symptoms for IBS                                                                                       Response(SGA)\
                                       C:20.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Global symptoms score\
                                       A:23.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Bloating(a 6-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(a 6-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B42]   2007   France               C:100                 Rome II                       Primary care                                    267           29/106              39/93                    49.3 ± 11.4                                  Combination                                                                                                  B. animalis DN173010 (1.25×10^10^ c.f.u./125 g) S. thermophilus (1.2×109 c.f.u./125 g) and L. bulgaricus (1.2×109 c.f.u./125 g) b.i.d.   6 weeks                                                                     improvement at least 10% vs. baseline                                                                                                                                          Response(improvement at least 10% vs. baseline)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Global symptoms score(a 7-pointLikert score)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(a 7-Likert score)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(a 7-Likert score)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B43]   2007   France               D:29\                 Rome II                       Not stated                                      100           8/40                16/36                    45.4 ± 14                                    Combination                                                                                                  1 × 10^10^                                                                                                                               4 weeks                                                                     Satisfactory relief of global IBS symptoms                                                                                                                                     Satisfactory relief of IBS symptoms\
                                       C:29\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Abdominal pain(a 4-pointLikert score)
                                       A:41\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                       non-classified:1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  [@B49]   2008   Germany              all types             Primary care physicians       Primary care                                    297           77/72               73/75                    49.6 ± 13.6                                  Enterococcus faecalis DSM16440 and Escherichia coli DSM17252                                                 (3.0-9.0×10^7^c.f.u./1.5 ml)×0.75 ml t.i.d. for 1 week, then 1.5 ml t.i.d. for weeks 2 and 3, then 2.25 ml t.i.d. for weeks 3--8         8 weeks                                                                     50% improvement in IBS global symptoms,and continuous scale symptoms for IBS                                                                                                   Response(50% improvement in IBS global symptoms)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Global symptoms score(GSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B45]   2008   Finland              D:45\                 Rome II                       Primary care                                    86            2/41                4/39                     48 ± 13                                      Combination                                                                                                  1 × 10^7^                                                                                                                                20 weeks                                                                    Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score\
                                       C:30\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Flatulence(a 5-point numerical scale)\
                                       A:25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Distension(a 5-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    abdominal pain(a 5-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B46]   2008   Korea                D:20\                 Rome III                      Secondary care                                  40            6/14                8/12                     44.7 ± 13                                    L. acidophilus SDC 2012 and 2013                                                                             4×10^9^                                                                                                                                  4 weeks                                                                     Any reduction in abdominal pain score                                                                                                                                          Response(Any reduction in abdominal pain score)\
                                       C:27.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Abdominal pain(a 6-point numerical scale)\
                                       M:62.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Adverse events

  [@B47]   2008   China                D:100                 Rome II                       Tertiary care                                   29            10/4                9/6                      45.2 ± 10.7                                  Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum   S.thermophilus (4×10^10^ c.f.u.),\                                                                                                       4 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score\
                                                                                                                                                                                                                                                                                                                                                                L. bulgaricus (4×10^9^ c.f.u.),\                                                                                                                                                                                                                                                                                                                                                                    Bloating(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                L. acidophilus (4×10^9^ c.f.u.),\                                                                                                                                                                                                                                                                                                                                                                   Abdominal pain(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                and B. longum (4×10^9^ c.f.u.)                                                                                                                                                                                                                                                                                                                                                                      Adverse events

  [@B48]   2009   UK                   C:100                 Rome III                      Tertiary care                                   34            0/17                0/17                     39.4 ± 10.6                                  Bifidobacterium lactis DN-173 010\                                                                           B. lactis DN-173 010(2.5×10^10^ c.f.u.),\                                                                                                4 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score\
                                                                                                                                                                                                                                                   Streptococcus thermophilus\                                                                                  S.thermophilus (2.4×10^9^ c.f.u.),\                                                                                                                                                                                                                                                                                                                                                                 Bloating(a 6-point numerical scale)\
                                                                                                                                                                                                                                                   and Lactobacillus bulgaricus                                                                                 L. bulgaricus (2.4×10^9^ c.f.u.),                                                                                                                                                                                                                                                                                                                                                                   Flatulence(a 6-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(a 6-point numerical scale)

  [@B50]   2009   Germany              All types             Kruis score                   Primary care                                    298           76/72               75/75                    49.6 ± 13.6                                  E. coli DSM17252                                                                                             (1.5--4.5×10^7^ c.f.u./ml) 0.75 ml drops t.i.d. for 1 week, then 1.5 ml t.i.d. for weeks 2--8                                            8 weeks                                                                     No longer having IBS symptoms                                                                                                                                                  Response(no longer having IBS symptoms)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    General symptom score\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B50]   2009   Korea                D:45.7\               Rome III                      tertiary care                                   70            25/11               22/12                    37 ± 14.85                                   Combination                                                                                                  4×10^10^                                                                                                                                 8 weeks                                                                     Reduction of symptom score by at least 50%                                                                                                                                     Response(Reduction of symptom score by at least 50%)\
                                       C:20\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Adverse events
                                       M:8.6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                       non-classified:25.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  [@B51]   2009   UK                   D:11.5C:27\           Rome II                       Advertising                                     52            3/25                4/20                     39 ± 11.5                                    Combination                                                                                                  2.5×10^10^                                                                                                                               8 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptom score
                                       A:61.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  [@B52]   2010   Sweden               D:35\                 Rome II                       Tertiary care                                   74            11/26               11/26                    43 ± 15.43                                   Combination                                                                                                  2×10^10^                                                                                                                                 8 weeks                                                                     Adequate relief of their IBS symptoms at least 50% of the weeks                                                                                                                Response(Adequate relief of their IBS symptoms)\
                                       C:15\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Global symptom score\
                                       M:50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Abdominal pain(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B53]   2011   Korea                D:71.6\               Rome II                       Tertiary care                                   90            18/17               19/20                    40.4 ± 12.9                                  Saccharomyces boulardii                                                                                      4×10^11^                                                                                                                                 4 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score(7-point Likert scale)\
                                       M:28.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Bloating(7-point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(7-point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B54]   2011   Germany              D:21.3\               Rome III                      Secondary care and advertising                  122           19/41               21/41                    38.9 ± 12.75                                 B. bifidum MIMBb75                                                                                           1×10^9^                                                                                                                                  4 weeks                                                                     Improvement in average weekly global IBS symptom score of 1 or more for 50% of weeks, and continuous scale for IBS symptoms                                                    Response(Improvement in average weekly global IBS symptom score of 1 or more for 50% of weeks)\
                                       C:19.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Global symptoms score(7-point Likert score)\
                                       M:58.2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Bloating(7-point Likert scale)\
                                       non-classified:0.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Abdominal pain(7-point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B55]   2011   USA                  D:100                 Rome III                      Tertiary care                                   24            5/10                3/6                      21.8 ± 17                                    Combination                                                                                                  9×10^11^                                                                                                                                 8 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score(a clinical rating scale GSRS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(GSRS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(GSRS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B56]   2011   Denmark and Sweden   all types             Rome II                       Primary and secondary care                      52            7/20                6/19                     51.3± 9.5                                    Combination                                                                                                  2.5×10^10^                                                                                                                               8 weeks                                                                     Adequate relief of IBS symptoms and continuous scale for IBS symptoms                                                                                                          Adequate relief of IBS symptoms\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Global symptoms score(IBS SSI Francis et al)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(100-mm VAS)

  [@B57]   2012   Korea                D:100                 Rome III                      Tertiary care                                   50            12/13               14/11                    39.1 ± 11.76                                 Combination                                                                                                  1×10^10^                                                                                                                                 8 weeks                                                                     Adequate relief of their IBS symptoms at least 50% of the weeks\                                                                                                               Response(Adequate relief of their IBS symptoms at least 50% of the weeks)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     and continuous scale for IBS symptoms                                                                                                                                          Global symptoms score(10-point VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(10-point VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(10-point VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B58]   2012   China                D:48.3\               Rome III                      Tertiary care                                   60            11/26               7/16                     44.66 ± 15.23                                Combination                                                                                                  1.5×10^7^                                                                                                                                4 weeks                                                                     reduction of symptom score by at least 30%                                                                                                                                     Improvement in IBS symptoms
                                       C:20\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                       M:11.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                       non-classified:10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  [@B59]   2012   France               D:30\                 Rome III                      Tertiary care                                   50            5/20                10/15                    47.05± 10.98                                 Lactobacillus casei rhamnosus LCR35                                                                          6×10^8^                                                                                                                                  4 weeks                                                                     IBS severity score reduced by at least 50%                                                                                                                                     Response (IBS severity score reduced by at least 50%)\
                                       C:22\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Adverse events
                                       M:34\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                       U:14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B60]   2012   India                all types             Rome III                      Primary care                                    214           70/38               81/25                    37.28± 12.6                                  L. plantarum LP299V DSM 9843                                                                                 1×10^11^                                                                                                                                 4 weeks                                                                     Patients rated treatment efficacy as excellent or good                                                                                                                         Global assessment of treatment efficacy\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B61]   2012   Norway               D:37.5\               Rome II                       Secondary care                                  28            Not stated          Not stated               50± 11                                       L. plantarum MF 1298                                                                                         1×10^10^                                                                                                                                 3 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score
                                       C:6.25\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                       A:56.25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B62]   2012   Germany              all types             Rome II                       Tertiary care                                   120           12/48               16/44                    45.7± 12.4                                   E. coli Nissle 1917                                                                                          2.5--25×10^9^ for 4 days then 5--50×10^9^ for 12 weeks                                                                                   12 weeks                                                                    Patients reported contented with treatment                                                                                                                                     Response (Patients reported contented with treatment)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B63]   2013   Iran                 all types             Rome III                      Secondary care                                  102           21/32               15/24                    41.8± 12.5                                   Lactobacillus reuteri                                                                                        1×10^11^                                                                                                                                 4 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Abdominal pain(questionare)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(questionare)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B64]   2013   Denmark              D:40\                 Rome III                      Primary care                                    131           51/16               46/18                    30.52± 9.42                                  Combination                                                                                                  5.2×10^10^                                                                                                                               6 months                                                                    Adequate relief of global IBS symptoms for at least 50% of the time, and continuous scale for IBS symptoms                                                                     Response (Adequate relief of global IBS symptoms)\
                                       C:19\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Global symptoms score\
                                       M:38\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Abdominal pain(GSRS-IBS)\
                                       U:2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Bloating(GSRS-IBS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B25]   2013   Ireland              all types             Rome II                       Population based                                76            8/31                6/31                     45.5± 11                                     B. infantis 35624                                                                                            1×10^9^                                                                                                                                  8 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptom severity(a six-point scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain((a six-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(a six-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B65]   2013   UK                   C and M               ROME III                      Primary care                                    179           13/75               14/77                    44.18± 12.36                                 Bifidobacterium lactis CNCM I-2494\                                                                          2.5×10^10^\                                                                                                                              12 weeks                                                                    Subjective global assessment (SGA) of symptom relief                                                                                                                           Subjective global assessment (SGA) of symptom relief\
                                                                                                                                                                                                                                                   S. thermophilus and L. bulgaricus                                                                            2.4×10^9^\                                                                                                                                                                                                                                                                                                                                                                                          IBS-SSS\
                                                                                                                                                                                                                                                                                                                                                                2.4×10^9^                                                                                                                                                                                                                                                                                                                                                                                           Abdominal pain(6 point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(6 point Likert scale)

  [@B66]   2014   Pakistan             D:100                 Rome III                      Tertiary care                                   72            27/10               26/9                     35.4± 11.9                                   Saccharomyces boulardii                                                                                      3×10^9^                                                                                                                                  6 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Abdominal pain(a 4-point scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(a 4-point scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B67]   2014   India                all types             Rome III                      Secondary care                                  108           21/33               22/32                    36.7± 11.5                                   Combination                                                                                                  8×10^9^                                                                                                                                  4 weeks                                                                     Satisfactory relief of global IBS symptoms for at least 50% of the time                                                                                                        Relief of IBS symptoms\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(100-mm VAS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(100-mm VAS)

  [@B68]   2014   Spain                D:100                 Rome III                      Tertiary care                                   84            16/39               15/14                    46.8± 12.5                                   Combination                                                                                                  high dose (1-3×10^10^)\                                                                                                                  6 weeks                                                                     "Considerably relieved" or "completely relieved" of global IBS symptoms for at least 50% of the time                                                                           Health-related quality of life(a specifc questionnaire ranging from 1-100)\
                                                                                                                                                                                                                                                                                                                                                                low dose (3-6×10^9^)                                                                                                                                                                                                                                                                                                                                                                                Respond(relief of symptoms)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B69]   2014   Netherlands          all types             Rome III                      Secondary care and advertising                  40            6/15                7/12                     40.5± 14.4                                   Combination                                                                                                  5×10^9^                                                                                                                                  6 weeks                                                                     A 30% or greater improvement in mean symptom composite score(MSS)                                                                                                              Respond(mean symptom composite score MSS)

  [@B70]   2014   Denmark              D:38\                 Rome III                      Tertiary care                                   81            14/27               11/29                    Not stated                                   Lactobacillus rhamnosus GG                                                                                   1.2×10^10^                                                                                                                               6 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              IBS-SSS
                                       C:17.3\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                       A:40.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                       non-classified:4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  [@B71]   2014   Iran                 D:32.6\               Rome II                       Tertiary care                                   129           20/46               24/39                    36.2± 9.2                                    Combination                                                                                                  2×10^8^                                                                                                                                  2 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Abdominal pain(a 4-point scale)\
                                       C:45.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Distension(a 4-point scale)
                                       A:21.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  [@B26]   2014   UK                   D:37.6\               Rome III                      Primary care and secondary care                 186           40/84               17/45                    38.3± 10.6                                   Combination                                                                                                  2×10^8^/kg                                                                                                                               12 weeks                                                                    Patients reported mild or no symptoms                                                                                                                                          Respond(IBS-SSS)\
                                       C:21.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      IBS symptom severity scores (IBS-SSS)\
                                       M:35.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Abdominal pain(IBS-SSS)\
                                       U:5.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Bloating(IBS-SSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B72]   2014   South Africa         D:37.6\               Rome II                       Secondary care                                  81            2/52                0/27                     47.9± 13                                     Lactobacillus plantarum 299 v                                                                                1×10^10^                                                                                                                                 8 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              IBS symptom severity scores (IBS-SSS)\
                                       C:21.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Adverse events

  [@B76]   2014   Korea                D:53.1\               Rome III                      Tertiary care                                   49            11/14               6/18                     44.5± 14.3                                   Combination                                                                                                  1×10^10^                                                                                                                                 4 weeks                                                                     Global relief of IBS symptoms                                                                                                                                                  Global relief of IBS symptoms\
                                       C40.8\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Abdominal pain(a 10-point numerical scale)\
                                       M:6.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Bloating(a 10-point numerical scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B74]   2015   Iran                 D:35.3\               Rome II                       Secondary care                                  139           Not stated          Not stated               38± 13.3                                     Escherichia coli Nissle 1917                                                                                 Not stated                                                                                                                               6 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Global symptoms score(Birmingham IBS Symptom Questionnaire)
                                       C39.6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                       M:25.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  [@B75]   2015   France               D:28.5\               Rome III                      Not stated                                      179           14/72               11/82                    44± 13.3                                     Saccharomyces cerevisiae CNCM I-3856                                                                         4×10^9^                                                                                                                                  8 weeks                                                                     A reduction in the abdominal pain score of 1 arbitrary unit (au) for at least 50% of the time                                                                                  Improvement in IBS symptoms\
                                       C46.9\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Abdominal pain(7-point Likert scale)\
                                       M:24.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Adverse events

  [@B76]   2015   Korea                D:48.1\               Rome III                      Tertiary care                                   80            24/17               19/20                    59.3± 12.2                                   Combination                                                                                                  1×10^10^                                                                                                                                 4 weeks                                                                     Adequate relief of global IBS symptoms                                                                                                                                         Adequate relief of global IBS symptoms\
                                       C:18.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Global symptoms score(10-point VAS)\
                                       M:21\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Abdominal pain(10-point VAS)\
                                       U:12.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Bloating(10-point VAS)

  [@B24]   2016   Finland              D:38.9\               Rome III                      Primary care                                    391           62/198              37/94                    47.9± 12.9                                   L.acidophilus NCFM (ATCC 700396)                                                                             low-dose: 1×10^9^\                                                                                                                       12 weeks                                                                    Continuous scale for IBS symptoms                                                                                                                                              IBS symptom severity scores (IBS-SSS)\
                                       C:16.6\                                                                                                                                                                                                                                                                                                                  high-dose: 1×10^10^                                                                                                                                                                                                                                                                                                                                                                                 Abdominal pain(IBS-SSS)\
                                       M:44\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Bloating(IBS-SSS)\
                                       U:0.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Adverse events

  [@B77]   2016   India                D:100                 Rome III                      Tertiary care                                   36            7/11                10/8                     35.8± 10.8                                   Bacillus coagulans MTCC 5856                                                                                 2×10^9^                                                                                                                                  90 days                                                                     Continuous scale for IBS symptoms                                                                                                                                              Abdominal pain(Questionnaire)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(Questionnaire)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B78]   2016   Italy                C:100                 Rome III                      Not stated                                      150           Not stated          Not stated               37.4± 12.5                                   1: L.acidophilus, L. reuteri\                                                                                1: 1×10^10^\                                                                                                                             60 days                                                                     A decrease of abdominal pain of at least 30% compared to the basal condition for at least 50% of the intervention time                                                         Response(the subject reporting a decrease of symptoms of at least 30% compared to the basal condition for at least 50% of the intervention time)
                                                                                                                                                                                                                                                   2: L.plantarum, L. rhamnosus, B. animalis subsp. Lactis                                                      2: 1.5×10^10^                                                                                                                                                                                                                                                                                                                                                                                       

  [@B18]   2016   France               D:20.8\               Rome III                      Primary care and secondary care                 379           31/161              31/156                   45.3± 14.9                                   Saccharomyces cerevisiae I-3856                                                                              8×10^9^                                                                                                                                  12 weeks                                                                    An improvement of 50% of the weekly average\'\'intestinal pain/discomfort score\'\' compared with baseline average score for at least 4 out of the last 8 weeks of the study   Response\
                                       C47.5\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Global symptoms score\
                                       M:31.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Abdominal pain(8-point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(8-point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B19]   2016   Netherlands          D:30\                 Rome II                       Secondary care,tertiary care, and advertising   80            13/26               12/29                    41.8± 14.1                                   Lactobacillus casei Shirota                                                                                  1.3×10^10^                                                                                                                               8 weeks                                                                     An mean symptom score(MSS) decrease of at least 30%                                                                                                                            Response (An mean symptom score(MSS) decrease of at least 30%)
                                       C:25\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                       A:28.75\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                       U:16.25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B20]   2017   Israel               D:100                 Rome III                      Community and secondary and tertiary care       107           0/54                0/53                     Not extractable                              Combination                                                                                                  5×10^10^                                                                                                                                 8 weeks                                                                     improvement in symptoms for at least 50%\                                                                                                                                      Response\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     of the tme                                                                                                                                                                     Adverse events

  [@B79]   2018   Bangladesh           D:100                 Rome III                      Tertiary care                                   360           136/45              145/34                   31.9 ± 9.9                                   Combination                                                                                                  8×10^9^                                                                                                                                  16weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              IBS symptom severity scores (IBS-SSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(IBS-SSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events

  [@B80]   2018   Iran                 D:100                 Rome III                      Secondary care and tertiary care                67            21/12               22/12                    34.1 ± 11.0                                  Combination                                                                                                  2×10^9^                                                                                                                                  6 months                                                                    Continuous scale for IBS symptoms                                                                                                                                              Abdominal pain(10-point VAS)

  [@B81]   2018   Korea                not stated            not stated                    Advertising                                     42            19/11               6/6                      32.7 ± 6.6                                   Lactobacillus gasseri BNR17                                                                                  low-dose: 1×10^9^\                                                                                                                       4 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              Abdominal pain(5-point Likert scale)\
                                                                                                                                                                                                                                                                                                                                                                high-dose: 1×10^10^                                                                                                                                                                                                                                                                                                                                                                                 Bloating(5-point Likert scale)

  [@B82]   2018   USA                  D:46.4\               Rome III                      Tertiary care                                   113           47/29               21/16                    40.4 ± 13.5                                  Combination                                                                                                  1×10^11^                                                                                                                                 6 weeks                                                                     Continuous scale for IBS symptoms                                                                                                                                              IBS symptom severity scores (IBS-SSS)\
                                       C:35.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Abdominal pain(IBS-SSS)\
                                       M:18.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Adverse events

  [@B83]   2018   China                D:100                 Rome III                      Tertiary care                                   200           63/42               53/42                    43.9 ± 12.7                                  Clostridium butyricum                                                                                        5.67×10^7^                                                                                                                               4 weeks                                                                     A reduction of ≥50 points of total IBS-SSS score                                                                                                                               Response (A reduction of ≥50 points of total IBS-SSS score)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    IBS symptom severity scores (IBS-SSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Abdominal pain(IBS-SSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Bloating(IBS-SSS)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adverse events
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Efficacy of Probiotics on IBS Symptoms Improvement or Response {#s3_1}
--------------------------------------------------------------

Thirty-five RCTs ([@B31]; [@B32]; [@B33]; [@B34]; [@B35]; [@B36]; [@B41]; [@B42]; [@B43]; [@B44]; [@B46]; [@B49]; [@B50]; [@B52]; [@B54]; [@B56]; [@B57]; [@B58]; [@B59]; [@B60]; [@B62]; [@B64]; [@B65]; [@B67]; [@B68]; [@B69]; [@B26]; [@B73]; [@B75]; [@B76]; [@B18]; [@B78]; [@B19]; [@B20]; [@B83]) with 4,392 patients reported overall IBS symptoms improvement or response as a dichotomous outcome. There were two ([@B68]; [@B78]) of these RCTs examining two different dose groups and one ([@B41]) examining three different dose groups. One ([@B31]) RCT did not mention the dose of probiotics, so it was not included in the subgroup analysis of probiotics dose. Overall, 1,171(49.5%) of 2,367 patients in the group of probiotics declared symptoms improvement or response after therapy, compared with 644 (31.8%) of 2,025 in the placebo group. The RR of IBS symptoms improvement or response was 1.52(95% CI 1.32--1.76), with high heterogeneity (I^2^ = 71%, P \< 0.001; [**Figure 4**](#f4){ref-type="fig"}). The funnel plot suggested the existence of asymmetry (Egger test, P = 0.094; [**Figure S1**](#SF1){ref-type="supplementary-material"}), indicating possible publication bias. While 19 RCTs ([@B34]; [@B35]; [@B36]; [@B43]; [@B46]; [@B50]; [@B52]; [@B54]; [@B56]; [@B60]; [@B62]; [@B64]; [@B65]; [@B26]; [@B68]; [@B75]; [@B78]; [@B18]; [@B20]) with low bias risk were assessed, the effect was still significant (RR = 1.59; 95% CI 1.25--2.04).
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In the subgroup of duration, 18 studies ([@B31]; [@B32]; [@B33]; [@B36]; [@B41]; [@B42]; [@B43]; [@B46]; [@B54]; [@B58]; [@B59]; [@B60]; [@B67]; [@B68]; [@B69]; [@B73]; [@B76]; [@B83]) evaluated a shorter duration (\< 8 weeks) and 17 studies ([@B34]; [@B35]; [@B44]; [@B49]; [@B50]; [@B52]; [@B56]; [@B57]; [@B62]; [@B64]; [@B65]; [@B26]; [@B75]; [@B78]; [@B18]; [@B19]; [@B20]) used a longer duration (≥ 8 weeks). The RR of group with less than 8 weeks was 1.55 (95% CI 1.27--1.89; [**Figure 4**](#f4){ref-type="fig"}), and the RR of group with more than 8 weeks was 1.52 (95% CI 1.23--1.88), with significant heterogeneity (I^2^ = 74%, P \< 0.01; I^2^ = 69%, P \< 0.01, respectively). In the subgroup of probiotics dose, high doses (daily dose of probiotics ≥ 10^10^) were assessed in 21 trials ([@B33]; [@B34]; [@B36]; [@B41]; [@B42]; [@B43]; [@B50]; [@B52]; [@B56]; [@B57]; [@B60]; [@B62]; [@B64]; [@B65]; [@B26]; [@B68]; [@B73]; [@B76]; [@B78]; [@B19]; [@B20]). A significant effect on symptoms (RR = 1.51; 95% CI 1.20--1.91; [**Figure S2**](#SF2){ref-type="supplementary-material"}) and statistically significant heterogeneity (I^2^ = 77%, P \< 0.01) were suggested. Low doses (daily dose of probiotics \< 10^10^) were evaluated in 15 trials ([@B32]; [@B35]; [@B41]; [@B44]; [@B46]; [@B49]; [@B54]; [@B58]; [@B59]; [@B67]; [@B68]; [@B69]; [@B75]; [@B18]; [@B83]). A significant effect on symptoms (RR = 1.56; 95% CI 1.33--1.83) and significant heterogeneity were also detected (I^2^ = 54%, P \< 0.01). In the subgroup of probiotics type, there were 15 studies using single probiotics ([@B31]; [@B32]; [@B33]; [@B41]; [@B46]; [@B49]; [@B54]; [@B59]; [@B60]; [@B62]; [@B75]; [@B78]; [@B18]; [@B19]; [@B83]) and 21 studies using combination probiotics ([@B34]; [@B35]; [@B36]; [@B42]; [@B43]; [@B44]; [@B50]; [@B52]; [@B56]; [@B57]; [@B58]; [@B64]; [@B65]; [@B67]; [@B68]; [@B69]; [@B26]; [@B73]; [@B76]; [@B78]; [@B20]). The RR of single and combination group was 1.76 (95% CI 1.37--2.25; [**Figure S3**](#SF3){ref-type="supplementary-material"}) and 1.39 (95% CI 1.18--1.65), respectively. The I^2^ of the single probiotics subgroup was 69% (P \< 0.01), and combination probiotics subgroup was 60% (P \< 0.01), suggesting statistically significant heterogeneity. In the subgroup of geographic position, we assigned 2 trials ([@B34]; [@B36]) in USA to the North America group; five comparisons of three separate papers ([@B41]; [@B65]; [@B26]) in UK, five trials ([@B42]; [@B43]; [@B59]; [@B75]; [@B18]) in France, and two trials ([@B69]; [@B19]) in Netherlands to the Western Europe group; two comparisons of one papers ([@B68]) in Spain and two comparisons of one papers ([@B78]) in Italy to the South Europe group; two trials ([@B31]; [@B64]) in Denmark, two trials ([@B32]; [@B52]) in Sweden, one trials ([@B56]) in Denmark and Sweden, and one trials ([@B35]) in Finland to the Northern Europe group; one trials ([@B33]) in Poland and four trials ([@B44]; [@B49]; [@B54]; [@B62]) in Germany to the Central Europe group; five trials ([@B46]; [@B50]; [@B57]; [@B73]; [@B76]) in Korea and two trials ([@B58]; [@B83]) in China to the East Asian group; one trials ([@B20]) in Israel to the West Asian group; and two trials ([@B60]; [@B67]) in India to the South Asian group. There was a statistically significant benefit in favor of probiotics in North America group (RR = 1.19; 95% CI 0.66--2.15; [**Figure 5**](#f5){ref-type="fig"}), with no significant heterogeneity noted between the studies(I^2^ = 0%, P = 0.48), West Europe group(RR = 1.15; 95% CI 1.01--1.30; I^2^ = 25%, P = 0.20), Northern Europe group(RR = 1.45; 95% CI 1.10--1.91; I^2^ = 33%, P = 0.19) and East Asian group(RR = 1.55; 95% CI 1.21--1.98; I^2^ = 39%, P = 0.13).

![Forest plot of efficacy of probiotics on IBS symptoms improvement or respond: subgroup of geographic position.](fphar-11-00332-g005){#f5}

Efficacy of Probiotics on Global IBS Symptoms Scores {#s3_2}
----------------------------------------------------

There were 29 separate trials ([@B34]; [@B35]; [@B37]; [@B38]; [@B40]; [@B41]; [@B45]; [@B47]; [@B48]; [@B51]; [@B52]; [@B53]; [@B54]; [@B55]; [@B56]; [@B57]; [@B61]; [@B25]; [@B64]; [@B65]; [@B26]; [@B70]; [@B72]; [@B74]; [@B76]; [@B24]; [@B18]; [@B79]; [@B83]) including 35 comparisons with 3,726 patients reporting the efficacy of probiotics on global IBS symptoms scores. One ([@B18]) of these RCTs examining two different dose groups and one ([@B41]) examining three different dose groups. There was a trial ([@B74]) did not mention the dose of probiotics, so it was not included in the subgroup analysis of probiotics dose. Two types of probiotics were used in one trial ([@B38]), and three subtypes of IBS, including IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed patterns of constipation and diarrhea (IBS-M), were detected separately in one RCT ([@B18]). Probiotics had a statistically significant effect on improving the global IBS symptoms vs. placebo (SMD = -1.8; 95% CI -0.30 to -0.06; [**Figure 6**](#f6){ref-type="fig"}). Heterogeneity was significant (I^2^ = 65%, P \< 0.001). There was no significant asymmetry in funnel plot (Egger test, P = 0.689; [**Figure S4**](#SF4){ref-type="supplementary-material"}), indicating no proof of publication bias.

![Forest plot of efficacy on global IBS symptoms scores: subgroup of probiotics duration.](fphar-11-00332-g006){#f6}

In the subgroup of duration, 11 comparisons ([@B40]; [@B41]; [@B47]; [@B48]; [@B53]; [@B54]; [@B61]; [@B70]; [@B74]; [@B76]; [@B83]) evaluated a shorter treatment duration (\< 8 weeks). There was a beneficial effect on global IBS symptoms scores with probiotics (SMD -0.09; 95% CI -0.20 to 0.02) and low heterogeneity was found (I^2^ = 10%, P = 0.12). In the subgroup of probiotics dose, no significant differences were found, as shown in [**Figure S5**](#SF5){ref-type="supplementary-material"}. In the subgroup of probiotics type, 14 comparisons ([@B37]; [@B38]; [@B40]; [@B41]; [@B53]; [@B54]; [@B61]; [@B25]; [@B70]; [@B72]; [@B74]; [@B24]; [@B18]; [@B83]) using single probiotics were found a beneficial efficacy on global IBS symptoms scores (SMD -0.06; 95% CI -0.16 to 0.14; [**Figure 7**](#f7){ref-type="fig"}), with low heterogeneity (I^2^ = 33%, P = 0.12). In the subgroup of geographic position, we assigned 2 trials ([@B34]; [@B55]) in USA to the North America group; seven comparisons of five separate papers ([@B41]; [@B48]; [@B51]; [@B65]; [@B26]) in UK, three comparisons of 1 papers ([@B18]) in France, and three comparisons of two separate papers ([@B38]; [@B25]) in Ireland to the Western Europe group; two trials ([@B64]; [@B70]) in Denmark, two trials ([@B40]; [@B52]) in Sweden, one trials ([@B56]) in Denmark and Sweden, four comparisons of three papers ([@B35]; [@B45]; [@B24]) in Finland, and one trials ([@B61]) in Norway to the Northern Europe group; one trials ([@B54]) in Germany to the Central Europe group; three trials ([@B53]; [@B57]; [@B76]) in Korea and two trials ([@B47]; [@B83]) in China to the East Asian group; one trials ([@B37]) in Israel and one trials ([@B74]) in Iran to the West Asian group; and one trials ([@B79]) in Bangladesh to the South Asian group; and one trials ([@B72]) in South Africa to the South Africa group. There was a statistically significant benefit in favor of probiotics in North America group (SMD -0.25; 95% CI -0.82 to 0.32; [**Figure 8**](#f8){ref-type="fig"}), with no significant heterogeneity noted between the studies (I^2^ = 0%, P = 0.68), East Asian group (SMD -0.24; 95% CI -0.43 to -0.05; I^2^ = 0%, P = 0.81), and South Asian group (SMD 0.06; 95% CI -0.24 to 0.36; I^2^ = 0%, P = 0.45).

![Forest plot of efficacy on global IBS symptoms scores: subgroup of probiotics type.](fphar-11-00332-g007){#f7}

![Forest plot of efficacy of probiotics on global IBS symptoms scores: subgroup of geographic position.](fphar-11-00332-g008){#f8}

Efficacy of Probiotics on Individual Symptom Scores {#s3_3}
---------------------------------------------------

There were 38 trials ([@B32]; [@B34]; [@B35]; [@B36]; [@B38]; [@B39]; [@B41]; [@B42]; [@B43]; [@B45]; [@B46]; [@B47]; [@B48]; [@B51]; [@B52]; [@B53]; [@B54]; [@B55]; [@B56]; [@B57]; [@B63]; [@B64]; [@B25]; [@B65]; [@B66]; [@B67]; [@B71]; [@B26]; [@B73]; [@B75]; [@B76]; [@B18]; [@B24]; [@B77]; [@B79]; [@B80]; [@B81]; [@B83]) including 44 comparisons with 4,579 patients reporting efficacy of probiotics on abdominal pain. Probiotics had effect on improving abdominal pain (SMD -0.22; 95% CI -0.33 to -0.11; [**Figure S6**](#SF6){ref-type="supplementary-material"}), but significant heterogeneity existed (I^2^ = 70%, P \< 0.001). However, in subgroup analysis of probiotics dose, 24 comparisons ([@B34]; [@B36]; [@B38]; [@B39]; [@B41]; [@B42]; [@B43]; [@B47]; [@B48]; [@B51]; [@B52]; [@B53]; [@B55]; [@B56]; [@B57]; [@B63]; [@B64]; [@B65]; [@B26]; [@B73]; [@B76]; [@B24]; [@B81]) using high dose were found a significant benefit over placebo (SMD = -0.14; 95% CI -0.26 to -0.01; [**Figure S7**](#SF7){ref-type="supplementary-material"}), with low heterogeneity (I^2^ = 39%, P = 0.03). There was no significant asymmetry in funnel plot (Egger test, P = 0.235; [**Figure S8**](#SF8){ref-type="supplementary-material"}), indicating no proof of publication bias.

Twenty-nine trials ([@B32]; [@B34]; [@B36]; [@B38]; [@B39]; [@B41]; [@B42]; [@B47]; [@B48]; [@B51]; [@B52]; [@B53]; [@B54]; [@B55]; [@B57]; [@B63]; [@B64]; [@B25]; [@B65]; [@B26]; [@B66]; [@B67]; [@B73]; [@B76]; [@B77]; [@B24]; [@B18]; [@B81]; [@B83]) reported continuous data for the effect of probiotics on bloating scores in 3,496 patients. Probiotics had effect on improving bloating (SMD -0.13; 95% CI -0.24 to -0.03; [**Figure S9**](#SF9){ref-type="supplementary-material"}) and heterogeneity was found (I^2^ = 54%, P \< 0.01). In the subgroup of probiotics duration, 19 comparisons ([@B32]; [@B39]; [@B41]; [@B42]; [@B47]; [@B48]; [@B53]; [@B54]; [@B63]; [@B66]; [@B67]; [@B73]; [@B76]; [@B81]; [@B83]) using a short treatment duration (\<8 weeks) were found a significant benefit over placebo (SMD -0.13; 95% CI -0.27 to -0.01). Low heterogeneity was detected (I^2^ = 47%, P = 0.01).There was a beneficial effect on bloating in 22 comparisons ([@B34]; [@B36]; [@B38]; [@B39]; [@B41]; [@B42]; [@B47]; [@B48]; [@B51]; [@B52]; [@B53]; [@B55]; [@B57]; [@B63]; [@B64]; [@B65]; [@B26]; [@B73]; [@B76]; [@B24]; [@B81]) using high dose (SMD -0.07; 95% CI -0.20 to -0.06; [**Figure S10**](#SF10){ref-type="supplementary-material"}).Low heterogeneity among trials was discovered (I^2^ = 38%, P = 0.04).The funnel plot suggested the existence of asymmetry (Egger test, P = 0.095; [**Figure S11**](#SF11){ref-type="supplementary-material"}), indicating possible publication bias.

Safety of Probiotics in IBS {#s3_4}
---------------------------

Forty studies ([@B31]; [@B33]; [@B34]; [@B35]; [@B36]; [@B37]; [@B38]; [@B39]; [@B41]; [@B42]; [@B44]; [@B45]; [@B46]; [@B47]; [@B49]; [@B50]; [@B52]; [@B53]; [@B54]; [@B55]; [@B57]; [@B59]; [@B60]; [@B62]; [@B63]; [@B64]; [@B25]; [@B66]; [@B68]; [@B26]; [@B72]; [@B73]; [@B75]; [@B24]; [@B77]; [@B18]; [@B20]; [@B79]; [@B82]; [@B83]) provided safety-related data, which was assessed by adverse events. Fourteen trials ([@B31]; [@B33]; [@B34]; [@B35]; [@B36]; [@B39]; [@B46]; [@B52]; [@B55]; [@B59]; [@B68]; [@B76]; [@B20]; [@B79]) reported that there were no adverse events. Four trials ([@B38]; [@B41]; [@B77]; [@B18]) reported adverse events of both arms. Difference was detected between probiotics and placebo (RR = 1.07; 95% CI 0.92--1.24; [**Figure 9**](#f9){ref-type="fig"}), with low heterogeneity (I^2^ = 0, P = 0.83). The funnel plot suggested no evidence of asymmetry (Egger test, P = 0.808; [**Figure S12**](#SF12){ref-type="supplementary-material"}). Probiotics seem to be safer than placebo in IBS patients.

![Forest plot of safety of probiotics in IBS.](fphar-11-00332-g009){#f9}

Discussion {#s4}
==========

Alterations of the intestinal microbiome could be relevant to IBS. Symptoms in IBS often developed after an infection, which was known as post-infectious IBS ([@B85]; [@B84]). Gut bacterial overgrowth may cause symptoms of IBS indistinguishable ([@B86]). Studies suggest that compared with the healthy group the colonic microbiome changes in IBS ([@B15]; [@B16]). Despite there were many drugs and treatments for IBS, probiotics have shown beneficial ([@B21]; [@B87]). Probiotics may regulate immunity in IBS to protect the intestine ([@B88]). Probiotics also modify the gut microbiota, which improves some IBS symptoms, such as flatulence, bloating, and altered bowel habits ([@B89]; [@B90]).

Summary of Main Results {#s4_1}
-----------------------

Many pieces of evidence have suggested that probiotics may benefit IBS symptoms ([@B71]; [@B72]; [@B73]). However, the results of clinical trials have been conflicting. Our meta-analysis has indicated that probiotics may be beneficial and safe to improve symptoms of IBS compared with placebo. However, it was difficult to draw a precise conclusion as a result of the existence of significant heterogeneity and possible publication bias. We found that a shorter treatment duration (\< 8 weeks) could reduce global IBS symptoms scores and bloating scores ([@B41]; [@B42]; [@B43]). As a chronic and recurrent disease ([@B83]), the improvement of IBS symptoms seems to be detected after a long time by taking probiotics continuously. However, according to current research shorter treatment duration seemed to be more beneficial. But due to many dropouts in the longer duration group, there may have an impact on research results, manifesting as greater improvement in the shorter duration group ([@B65]). Although the use of single probiotics tended to have a beneficial effect on improving the bloating scores ([@B77]; [@B18]; [@B81]; [@B83]), it was unknown which strain or species was more beneficial than others. Using a high dose of probiotics may reduce abdominal pain scores and bloating scores ([@B73]; [@B76]; [@B81]). However, Lyra et al. tested two different doses (10^10^ CFU/D, and 10^9^ CFU/D) of Lactobacillus acidophilus NCFM and reported that none of the outcomes showed a dose-response effect ([@B24]). Small differences of dosage may contribute to no effect of dose. Probiotics could benefit overall IBS symptoms improvement in North America, West Europe, Northern Europe, and East Asian.We also found that probiotics could reduce global IBS symptoms scores in North America, East Asian, and South Asian. More pieces of evidence are needed. Probiotics seemed safe for patients with irritable bowel syndrome ([@B38]; [@B41]; [@B77]; [@B18]), but more long-term trials are required to prove it.

Strengths and Weaknesses {#s4_2}
------------------------

Our meta-analysis is the first to assemble the efficacy and safety of probiotics for IBS patients with all diagnostic criteria by subgroup analyses of probiotic type, dose, treatment duration, and geographic position. We conducted this meta-analysis and systematic review using a rigorous and reproducible methodology. Two reviewers assessed eligibility and extracted data independently. The random-effects model was used to minimize the possibility of overestimating treatment results. We also tried to contact researchers of possibly eligible trials to get data. These comprehensive approaches included more than 3,300 IBS patients receiving probiotics treatment. Finally, subgroup analyses of probiotics type, dose, treatment duration, and geographic position were performed to evaluate the efficacy of treatment.

Our study has certain limitations. Bias risk of many studies was unknown, and the analysis shows considerable evidence of heterogeneity between trials. However, considering only studies with low bias risk, the positive effects remained. The number of studies on subgroup analyses of probiotics type, doses, and treatment duration was limited. It was not enough to detect significant differences in the efficacy of probiotics. In some studies, significant placebo effects have been found which can affect the results.

Conclusions {#s5}
===========

In summary, this meta-analysis has demonstrated moderate evidence for the use and safety of probiotics in IBS. A shorter treatment duration (\< 8 weeks) and a single probiotic may be more beneficial. Probiotics seem to be safe for patients with irritable bowel syndrome. There is still a need for more clinical trials. Finally, probiotics may be a beneficial therapy for IBS patients.
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